Molecular targets of botulinum toxin at the mammalian neuromuscular junction

被引:24
作者
Whelchel, DD [1 ]
Breluner, TM [1 ]
Brooks, PM [1 ]
Coffield, JA [1 ]
机构
[1] Univ Georgia, Coll Vet Med, Dept Physiol & Pharmacol, Athens, GA 30602 USA
关键词
Botulinum neurotoxin; neuromuscular junction; paralysis; SNAP-25; VAMP; sprouting;
D O I
10.1002/mds.20004
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The molecular targets of botulinum neurotoxins (BoNTs) are SNARE (soluble N-ethylmaleimide-sensitive factor-attachment protein-receptor) proteins necessary for neurotransmitter release. BoNT are powerful therapeutic agents in the treatment of numerous neurological disorders. The goals of this study were to (1) assess toxin diffusion by measuring substrate cleavage in adjacent and distant muscles, and (2) characterize the clinical course using SNARE protein chemistry. A small volume of BoNT/A was injected unilaterally into the mouse gastrocnernius muscle. Motor impairment was limited to the toxin-treated limb. No systemic illness or deaths occurred. At five time points, a subset of mice were killed, and muscles from both hindlimbs, and the diaphragm, were collected. Protein samples were examined for changes in SNAP-25 (synaptosomal-associated protein of Mr = 25 kDa) using immunochemistry. SNAP-25 cleavage product was noted in the toxin-treated limb as early as 1 day postinjection and continued through day 28. Onset and peak levels of substrate cleavage corresponded to the onset and peak clinical response. Cleavage was observed in adjacent and distant muscles, demonstrating that substrate cleavage is a sensitive indicator of toxin diffusion. Significant increases in full-length SNAP-25 and vesicle-associated membrane protein II were evident early in the impaired limb and continued through day 28. The increased SNARE protein most likely originates from nerve terminal sprouts. (C) 2004 Movement Disorder Society.
引用
收藏
页码:S7 / S16
页数:10
相关论文
共 42 条
  • [1] Adler CH, 2000, NEUROLOGY, V55, pS9
  • [2] Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle
    Adler, M
    Keller, JE
    Sheridan, RE
    Deshpande, SS
    [J]. TOXICON, 2001, 39 (2-3) : 233 - 243
  • [3] Incorporation of synaptotagmin II to the axolemma of botulinum type-A poisoned mouse motor endings during enhanced quantal acetylcholine release
    Angaut-Petit, D
    Molgó, J
    Faille, L
    Juzans, P
    Takahashi, M
    [J]. BRAIN RESEARCH, 1998, 797 (02) : 357 - 360
  • [4] TERMINAL SPROUTING IN MOUSE NEUROMUSCULAR-JUNCTIONS POISONED WITH BOTULINUM TYPE-A TOXIN - MORPHOLOGICAL AND ELECTROPHYSIOLOGICAL FEATURES
    ANGAUTPETIT, D
    MOLGO, J
    COMELLA, JX
    FAILLE, L
    TABTI, N
    [J]. NEUROSCIENCE, 1990, 37 (03) : 799 - 808
  • [5] Muscle fiber atrophy in leg muscles after botulinum toxin type A treatment of cervical dystonia
    Ansved, T
    Odergren, T
    Borg, K
    [J]. NEUROLOGY, 1997, 48 (05) : 1440 - 1442
  • [6] A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice
    Aoki, KR
    [J]. TOXICON, 2001, 39 (12) : 1815 - 1820
  • [7] Analgesic effects of botulinum toxin A: a randomized, placebo-controlled clinical trial
    Barwood, S
    Baillieu, C
    Boyd, R
    Brereton, K
    Low, J
    Nattrass, G
    Graham, HK
    [J]. DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY, 2000, 42 (02) : 116 - 121
  • [8] Generalised muscular weakness after botulinum toxin injections for dystonia:: a report of three cases
    Bhatia, KP
    Münchau, A
    Thompson, PD
    Houser, M
    Chauhan, VS
    Hutchinson, M
    Shapira, AHV
    Marsden, CD
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 67 (01) : 90 - 93
  • [9] BOTULINUM NEUROTOXIN-A SELECTIVELY CLEAVES THE SYNAPTIC PROTEIN SNAP-25
    BLASI, J
    CHAPMAN, ER
    LINK, E
    BINZ, T
    YAMASAKI, S
    DECAMILLI, P
    SUDHOF, TC
    NIEMANN, H
    JAHN, R
    [J]. NATURE, 1993, 365 (6442) : 160 - 163
  • [10] BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x